A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

Part of paid clinical trials in Glendale, California.

Sponsor
Novo Nordisk A/S
Study ID
NCT07566390
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • NNC0113-5840 — DRUG
    NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin.
  • Placebo — DRUG
    Placebo matched to NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin.

Study Details

The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.

Key Dates

Start date
May 1, 2026
Status verified
May 2026
Primary completion
Nov 26, 2026
Completion
Nov 26, 2026

Study Design

Enrollment
48 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1 NNC0113-5840
    Participants will be randomized to receive NNC0113-5840 single dose level 1 subcutaneously.
  • Experimental: Cohort 2 NNC0113-5840
    Participants will be randomized to receive NNC0113-5840 single dose level 2 subcutaneously.
  • Experimental: Cohort 3 NNC0113-5840
    Participants will be randomized to receive NNC0113-5840 single dose level 3 subcutaneously.
  • Experimental: Cohort 4 NNC0113-5840
    Participants will be randomized to receive NNC0113-5840 single dose level 4 subcutaneously.
  • Experimental: Cohort 5 NNC0113-5840
    Participants will be randomized to receive NNC0113-5840 single dose level 5 subcutaneously.
  • Experimental: Cohort 6 NNC0113-5840
    Participants will be randomized to receive NNC0113-5840 single dose level 6 subcutaneously.
  • Placebo Comparator: Placebo matching NNC0113-5840
    Participants will receive placebo matched to NNC0113-5840 subcutaneously.

Primary Outcome Measure

Number of treatment emergent adverse events (TEAEs) [ Time Frame: From time of dosing (day 1) up to day 43 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
PAREXEL Glendale/LA EPCUGlendaleCalifornia91206-

Find similar trials in Glendale, CA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
PAREXEL Glendale/LA EPCU· Glendale, CA

Related Studies